Abstract
Background: HIV treatment programs in Africa typically approach all enrolling patients uniformly. Growing numbers of patients are antiretroviral experienced. Defining patients on the basis of antiretroviral experience may inform enrollment practices, particularly if medical outcomes differ. Methods: Baseline and follow-up measures (CD4, weight change, and survival) were compared in a retrospective analysis between antiretroviral-naive (ARV-N) and antiretroviral experience (ARV-E) patients enrolled at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya and followed between January 2004 and August 2006. Results: 1,307 ARV-N and 962 ARV-E patients receiving highly active antiretroviral therapy (HAART) were followed for median of 9 months (interquartile range: 4-16 months). Compared to ARV-N, ARV-E had substantially higher CD4 count (median cells/mm3, 193 versus 95, P < 0.001) and weight (median kg, 62 versus 57, P < 0.001) at baseline, and lower rates of change in CD4 (-9.2 cells/mm3/month; 95% CI, -11.4 – -7.0) and weight (-0.24 kg/month; 95% CI, -0.35 – - 0.14) over 12 months. Mortality was significantly higher in ARV-N than ARV-E (P = 0.001). Conclusions: ARV-E patients form a growing group that differs significantly from ARV-N patients and requires a distinct approach from ARV-N clients. Systematic approaches to streamline care of ARV-E patients may allow focused attention on early ARV-N clients whose mortality risks are substantially higher.
Keywords: Africa, HAART, HIV-1, clinic flow, experience, mortality
Current HIV Research
Title: Impact of Prior HAART Use on Clinical Outcomes in a Large Kenyan HIV Treatment Program
Volume: 7 Issue: 4
Author(s): Michael H. Chung, Alison L. Drake, Barbra A. Richardson, Ashok Reddy, Joan Thiga, Samah R. Sakr, James N. Kiarie, Paul Yowakim and Grace C. John-Stewart
Affiliation:
Keywords: Africa, HAART, HIV-1, clinic flow, experience, mortality
Abstract: Background: HIV treatment programs in Africa typically approach all enrolling patients uniformly. Growing numbers of patients are antiretroviral experienced. Defining patients on the basis of antiretroviral experience may inform enrollment practices, particularly if medical outcomes differ. Methods: Baseline and follow-up measures (CD4, weight change, and survival) were compared in a retrospective analysis between antiretroviral-naive (ARV-N) and antiretroviral experience (ARV-E) patients enrolled at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya and followed between January 2004 and August 2006. Results: 1,307 ARV-N and 962 ARV-E patients receiving highly active antiretroviral therapy (HAART) were followed for median of 9 months (interquartile range: 4-16 months). Compared to ARV-N, ARV-E had substantially higher CD4 count (median cells/mm3, 193 versus 95, P < 0.001) and weight (median kg, 62 versus 57, P < 0.001) at baseline, and lower rates of change in CD4 (-9.2 cells/mm3/month; 95% CI, -11.4 – -7.0) and weight (-0.24 kg/month; 95% CI, -0.35 – - 0.14) over 12 months. Mortality was significantly higher in ARV-N than ARV-E (P = 0.001). Conclusions: ARV-E patients form a growing group that differs significantly from ARV-N patients and requires a distinct approach from ARV-N clients. Systematic approaches to streamline care of ARV-E patients may allow focused attention on early ARV-N clients whose mortality risks are substantially higher.
Export Options
About this article
Cite this article as:
Chung H. Michael, Drake L. Alison, Richardson A. Barbra, Reddy Ashok, Thiga Joan, Sakr R. Samah, Kiarie N. James, Yowakim Paul and John-Stewart C. Grace, Impact of Prior HAART Use on Clinical Outcomes in a Large Kenyan HIV Treatment Program, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680552
DOI https://dx.doi.org/10.2174/157016209788680552 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Current Strategies and Future Directions in Classification and Treatment of Uterine Sarcomas
Current Cancer Therapy Reviews Case Report: Escherichia fergusonnii - Pathogen in Urinary Tract Infection
Infectious Disorders - Drug Targets Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer
Current Cancer Drug Targets Various Müllerian-duct Anomalies in Women at Rural Tertiary Care Center of Northern India: An Observational Study
Current Women`s Health Reviews Towards Prevention of Ovarian Cancer
Current Cancer Drug Targets Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Current Molecular Medicine Origin and Evolution of China Pharmacopoeia and Its Implication for Traditional Medicines
Mini-Reviews in Medicinal Chemistry How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Discovery of New Inhibitors of Urease Enzyme: A Study Using STD-NMR Spectroscopy
Letters in Drug Design & Discovery Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Meet Our Editorial Board Member
Current Drug Therapy A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells
Combinatorial Chemistry & High Throughput Screening Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews Melanoma Adjuvant Treatment: Current Insight and Clinical Features
Current Cancer Drug Targets Endometriosis Management: Workflow on Genomics and Proteomics and Future Biomolecular Pharmacotherapy
Current Medicinal Chemistry Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets